NAGE vs. NVO

Last updated Apr 1, 2026

Compare and contrast key facts about Niagen Bioscience, Inc (NAGE) and Novo Nordisk A/S (NVO).

Performance

NAGE vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Niagen Bioscience, Inc (NAGE) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

NAGE vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NAGE Niagen Bioscience, Inc	-30.66%	19.89%	270.98%	-14.88%	-55.08%	-22.08%	11.37%	25.66%	-41.67%	77.64%
NVO Novo Nordisk A/S	-25.12%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	28.70%	-12.98%	52.92%

Fundamentals

Market Cap NAGE : $372.40M NVO : $163.46B
EPS NAGE : $0.20 NVO : $22.15
PE Ratio NAGE : 21.76 NVO : 1.66
PEG Ratio NAGE : 0.18 NVO : 0.07
PS Ratio NAGE : 2.92 NVO : 0.55
PB Ratio NAGE : 4.87 NVO : 0.84
Total Revenue (TTM) NAGE : $129.42M NVO : $297.20B
Gross Profit (TTM) NAGE : $83.19M NVO : $240.66B
EBITDA (TTM) NAGE : $16.64M NVO : $153.18B

Returns By Period

In the year-to-date period, NAGE achieves a -30.66% return, which is significantly lower than NVO's -25.12% return. Over the past 10 years, NAGE has underperformed NVO with an annualized return of 0.28%, while NVO has yielded a comparatively higher 5.13% annualized return.

NAGE

• 1D: 3.04%
• 1M: -12.67%
• YTD: -30.66%
• 6M: -52.73%
• 1Y: -36.09%
• 3Y*: 42.31%
• 5Y*: -14.57%
• 10Y*: 0.28%

NVO

• 1D: 4.14%
• 1M: 1.73%
• YTD: -25.12%
• 6M: -31.34%
• 1Y: -44.52%
• 3Y*: -20.64%
• 5Y*: 3.88%
• 10Y*: 5.13%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NAGE vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NAGE

NAGE Risk / Return Rank: 19
NAGE Sharpe Ratio Rank: 13
NAGE Sortino Ratio Rank: 15
NAGE Omega Ratio Rank: 16
NAGE Calmar Ratio Rank: 25
NAGE Martin Ratio Rank: 27

NVO

NVO Risk / Return Rank: 12
NVO Sharpe Ratio Rank: 8
NVO Sortino Ratio Rank: 11
NVO Omega Ratio Rank: 11
NVO Calmar Ratio Rank: 14
NVO Martin Ratio Rank: 14

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NAGE vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Niagen Bioscience, Inc (NAGE) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NAGE	NVO	Difference
Sharpe ratio Return per unit of total volatility	-0.64	-0.82	+0.18
Sortino ratio Return per unit of downside risk	-0.70	-1.02	+0.32
Omega ratio Gain probability vs. loss probability	0.92	0.86	+0.06
Calmar ratio Return relative to maximum drawdown	-0.49	-0.79	+0.30
Martin ratio Return relative to average drawdown	-0.80	-1.37	+0.57
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NAGE vs. NVO - Sharpe Ratio Comparison

The current NAGE Sharpe Ratio is -0.64, which is comparable to the NVO Sharpe Ratio of -0.82. The chart below compares the historical Sharpe Ratios of NAGE and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NAGE	NVO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.64	-0.82	+0.18
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.19	0.10	-0.29
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.00	0.16	-0.16
Sharpe Ratio (All Time) Calculated using the full available price history	-0.02	0.46	-0.48

Correlation

The correlation between NAGE and NVO is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NAGE vs. NVO - Dividend Comparison

NAGE has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 5.06%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NAGE Niagen Bioscience, Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	5.06%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Drawdowns

NAGE vs. NVO - Drawdown Comparison

The maximum NAGE drawdown since its inception was -97.00%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for NAGE and NVO.

Drawdown Indicators

	NAGE	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-97.00%	-74.70%	-22.30%
Max Drawdown (1Y) Largest decline over 1 year	-70.85%	-55.03%	-15.82%
Max Drawdown (5Y) Largest decline over 5 years	-89.10%	-74.70%	-14.40%
Max Drawdown (10Y) Largest decline over 10 years	-93.65%	-74.70%	-18.95%
Current Drawdown Current decline from peak	-76.47%	-73.25%	-3.22%
Average Drawdown Average peak-to-trough decline	-75.71%	-17.55%	-58.16%
Ulcer Index Depth and duration of drawdowns from previous peaks	43.39%	31.69%	+11.70%

Volatility

NAGE vs. NVO - Volatility Comparison

Niagen Bioscience, Inc (NAGE) has a higher volatility of 13.45% compared to Novo Nordisk A/S (NVO) at 9.88%. This indicates that NAGE's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NAGE	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.45%	9.88%	+3.57%
Volatility (6M) Calculated over the trailing 6-month period	34.51%	38.79%	-4.28%
Volatility (1Y) Calculated over the trailing 1-year period	56.34%	54.20%	+2.14%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	77.59%	37.82%	+39.77%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	79.94%	32.29%	+47.65%

Financials

NAGE vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between Niagen Bioscience, Inc and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NAGE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Niagen Bioscience, Inc reported a gross profit of 21.70M and revenue of 33.84M. Therefore, the gross margin over that period was 64.1%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a gross profit of 54.38B and revenue of 67.28B. Therefore, the gross margin over that period was 80.8%.

NAGE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Niagen Bioscience, Inc reported an operating income of 2.10M and revenue of 33.84M, resulting in an operating margin of 6.2%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported an operating income of 27.12B and revenue of 67.28B, resulting in an operating margin of 40.3%.

NAGE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Niagen Bioscience, Inc reported a net income of 4.13M and revenue of 33.84M, resulting in a net margin of 12.2%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a net income of 22.96B and revenue of 67.28B, resulting in a net margin of 34.1%.